Originally published as JCO Early Release 10.1200/JCO.2003.02.153 on July 14 2003

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ozols, R. F. Articles by Baergen, R. Search for Related Content PubMed PubMed Citation Articles by Ozols, R. F. Articles by Baergen, R. Social Bookmarking                            What's this?

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel Clarke-Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca Baergen

From Medical Science Department, Fox Chase Cancer Center, Philadelphia, PA; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo; Department of Pathology, New York Presbyterian Hospital-Cornell Medical Center, New York, NY; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecologic Oncology, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH; Gynecologic Oncology and Obstetrics and Gynecology Departments, Duke University School of Medicine, Durham, NC; Division of Gynecologic Oncology, University of California at Irvine, Orange, CA; Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Department of Obstetrics and Gynecology, Rush Medical Center, Chicago, IL; and Division of Gynecologic Oncology, University of Wisconsin, Madison, WI (affiliate of University of Texas Southwestern Medical Center at Dallas, Dallas, TX).

Address reprint requests to Denise Mackey, Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103; e-mail: dmackey{at}gog.org.

Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in nonrandomized trials, carboplatin and paclitaxel was a less toxic and highly active combination regimen, there remained concern regarding its efficacy in patients with small-volume, resected, stage III disease. Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population.

Patients and Methods: Patients with advanced ovarian cancer and no residual mass greater than 1.0 cm after surgery were randomly assigned to receive cisplatin 75 mg/m² plus a 24-hour infusion of paclitaxel 135 mg/m² (arm I), or carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m² over 3 hours (arm II).

Results: Seven hundred ninety-two eligible patients were enrolled onto the study. Prognostic factors were similar in the two treatment groups. Gastrointestinal, renal, and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I. Grade 2 or greater thrombocytopenia was more common in arm II. Neurologic toxicity was similar in both regimens. Median progression-free survival and overall survival were 19.4 and 48.7 months, respectively, for arm I compared with 20.7 and 57.4 months, respectively, for arm II. The relative risk (RR) of progression for the carboplatin plus paclitaxel group was 0.88 (95% confidence interval [CI], 0.75 to 1.03) and the RR of death was 0.84 (95% CI, 0.70 to 1.02).

Conclusion: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.

Supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Aebi, M. Castiglione, and On behalf of the ESMO Guidelines Working Group Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv21 - iv23. [Full Text] [PDF]

				A. Berchuck, E. S. Iversen, J. Luo, J. P. Clarke, H. Horne, D. A. Levine, J. Boyd, M. A. Alonso, A. A. Secord, M. Q. Bernardini, et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clin. Cancer Res., April 1, 2009; 15(7): 2448 - 2455. [Abstract] [Full Text] [PDF]

				M. G. Teneriello, P. C. Tseng, M. Crozier, C. Encarnacion, K. Hancock, M. J. Messing, K. A. Boehm, A. Williams, and L. Asmar Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1426 - 1431. [Abstract] [Full Text] [PDF]

				M. A. Bookman, M. F. Brady, W. P. McGuire, P. G. Harper, D. S. Alberts, M. Friedlander, N. Colombo, J. M. Fowler, P. A. Argenta, K. De Geest, et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup J. Clin. Oncol., March 20, 2009; 27(9): 1419 - 1425. [Abstract] [Full Text] [PDF]

				P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]

				G. FIORENTINI, M. FILIPPESCHI, G. TURRISI, A. MAMBRINI, P. G. GIANNESSI, M. D'ALESSANDRO, S. ROSSI, P. DENTICO, S. GUADAGNI, M. CANTORE, et al. Advanced Cancer of the Ovary: Intraperitoneal Chemotherapy as a New Therapeutical Option In Vivo, March 1, 2009; 23(2): 317 - 321. [Abstract] [Full Text] [PDF]

				D. Aoki, Y. Oda, S. Hattori, K.-i. Taguchi, Y. Ohishi, Y. Basaki, S. Oie, N. Suzuki, S. Kono, M. Tsuneyoshi, et al. Overexpression of Class III {beta}-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma Clin. Cancer Res., February 15, 2009; 15(4): 1473 - 1480. [Abstract] [Full Text] [PDF]

				A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann. Onc., February 1, 2009; 20(2): 294 - 297. [Abstract] [Full Text] [PDF]

				D. AOKI, Y. WATANABE, T. JOBO, K. USHIJIMA, K. HASEGAWA, N. SUSUMU, N. SUZUKI, R. AOKI, S. ISONISHI, S. SAGAE, et al. Favourable Prognosis with Modified Dosing of Docetaxel and Cisplatin in Japanese Patients with Ovarian Cancer Anticancer Res, February 1, 2009; 29(2): 561 - 566. [Abstract] [Full Text] [PDF]

				O. W. S. YAP, G. BHAT, L. LIU, and T. O. TOLLEFSBOL Epigenetic Modifications of the Estrogen Receptor {beta} Gene in Epithelial Ovarian Cancer Cells Anticancer Res, January 1, 2009; 29(1): 139 - 144. [Abstract] [Full Text] [PDF]

				J. L. Walker Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer ASCO Educational Book, January 1, 2009; 2009(1): 308 - 312. [Abstract] [Full Text] [PDF]

				L. J. Havrilesky, A. Alvarez Secord, K. M. Darcy, D. K. Armstrong, and S. Kulasingam Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 2008; 26(25): 4144 - 4150. [Abstract] [Full Text] [PDF]

				S. E. Johnatty, J. Beesley, J. Paul, S. Fereday, A. B. Spurdle, P. M. Webb, K. Byth, S. Marsh, H. McLeod, AOCS Study Group, et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5594 - 5601. [Abstract] [Full Text] [PDF]

				H. S. Kim, N.-H. Park, H. H. Chung, J. W. Kim, Y.-S. Song, and S.-B. Kang Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin? Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 445 - 450. [Abstract] [Full Text] [PDF]

				A. M. C. Swart, S. Burdett, J. Ledermann, P. Mook, and M. K. B. Parmar Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review Ann. Onc., April 1, 2008; 19(4): 688 - 695. [Abstract] [Full Text] [PDF]

				R. P. Rocconi, T. O. Kirby, R. S. Seitz, R. Beck, J. M. Straughn Jr, R. D. Alvarez, and W. K. Huh Lipoxygenase Pathway Receptor Expression in Ovarian Cancer Reproductive Sciences, March 1, 2008; 15(3): 321 - 326. [Abstract] [PDF]

				G. Ferrandina, M. Ludovisi, D. Lorusso, S. Pignata, E. Breda, A. Savarese, P. Del Medico, L. Scaltriti, D. Katsaros, D. Priolo, et al. Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 890 - 896. [Abstract] [Full Text] [PDF]

				C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]

				A. Prat, M. Parera, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, I. Roxana, J. Baselga, and J. M. Del Campo Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann. Onc., February 1, 2008; 19(2): 327 - 331. [Abstract] [Full Text] [PDF]

				A. N. Viswanathan, B. M. Buttin, and A. M. Kennedy Oncodiagnosis Panel: 2006: Ovarian, Cervical, and Endometrial Cancer RadioGraphics, January 1, 2008; 28(1): 289 - 307. [Full Text] [PDF]

				D. S. Chi, P. T. Ramirez, J. B. Teitcher, S. Mironov, D. M. Sarasohn, R. B. Iyer, E. L. Eisenhauer, N. R. Abu-Rustum, Y. Sonoda, D. A. Levine, et al. Prospective Study of the Correlation Between Postoperative Computed Tomography Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, and Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease 1 cm or Less J. Clin. Oncol., November 1, 2007; 25(31): 4946 - 4951. [Abstract] [Full Text] [PDF]

				M. Joerger, A. D.R. Huitema, D. J. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. B. Vermorken, E. Strocchi, A. Martoni, R. Sorio, et al. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin. Cancer Res., November 1, 2007; 13(21): 6410 - 6418. [Abstract] [Full Text] [PDF]

				S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod, and R. Brown Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4528 - 4535. [Abstract] [Full Text] [PDF]

				V. Mobus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion, R. Kimmig, H. Ostermann, A. Hinke, and J. A. Ledermann Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT J. Clin. Oncol., September 20, 2007; 25(27): 4187 - 4193. [Abstract] [Full Text] [PDF]

				R. F. Ozols Ovarian Cancer: Is Dose Intensity Dead? J. Clin. Oncol., September 20, 2007; 25(27): 4157 - 4158. [Full Text] [PDF]

				M. Markman Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action J. Clin. Oncol., September 20, 2007; 25(27): 4168 - 4170. [Full Text] [PDF]

				W. E. Winter III, G. L. Maxwell, C. Tian, J. W. Carlson, R. F. Ozols, P. G. Rose, M. Markman, D. K. Armstrong, F. Muggia, and W. P. McGuire Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., August 20, 2007; 25(24): 3621 - 3627. [Abstract] [Full Text] [PDF]

				G Ferrandina, M Ludovisi, R De Vincenzo, V Salutari, D Lorusso, M Colangelo, T Prantera, M. Valerio, and G Scambia Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study Ann. Onc., August 1, 2007; 18(8): 1348 - 1353. [Abstract] [Full Text] [PDF]

				M. Forster, S. Kaye, A. Oza, I. Sklenar, A. Johri, W. Cheung, S. Zaknoen, and M. Gore A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4178 - 4184. [Abstract] [Full Text] [PDF]

				S. Mabuchi, D. A. Altomare, M. Cheung, L. Zhang, P. I. Poulikakos, H. H. Hensley, R. J. Schilder, R. F. Ozols, and J. R. Testa RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4261 - 4270. [Abstract] [Full Text] [PDF]

				G. Rao, M. Crispens, and M. L. Rothenberg Intraperitoneal Chemotherapy for Ovarian Cancer: Overview and Perspective J. Clin. Oncol., July 10, 2007; 25(20): 2867 - 2872. [Abstract] [Full Text] [PDF]

				C. Trope and J. Kaern Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920. [Abstract] [Full Text] [PDF]

				S. S. Ramalingam, R. A. Parise, R. K. Ramananthan, T. F. Lagattuta, L. A. Musguire, R. G. Stoller, D. M. Potter, A. E. Argiris, J. A. Zwiebel, M. J. Egorin, et al. Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies Clin. Cancer Res., June 15, 2007; 13(12): 3605 - 3610. [Abstract] [Full Text] [PDF]

				G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]

				K. M. Darcy, C. Tian, and E. Reed A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy Cancer Res., May 1, 2007; 67(9): 4474 - 4481. [Abstract] [Full Text] [PDF]

				F Hilpert, A du Bois, E. Greimel, J Hedderich, G Krause, L Venhoff, S Loibl, and J Pfisterer Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany Ann. Onc., February 1, 2007; 18(2): 282 - 287. [Abstract] [Full Text] [PDF]

				O Tredan, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Ann. Onc., February 1, 2007; 18(2): 256 - 262. [Abstract] [Full Text] [PDF]

				M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis, and J. P. A. Ioannidis Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. J Natl Cancer Inst, November 15, 2006; 98(22): 1655 - 1663. [Abstract] [Full Text] [PDF]

				J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stahle, G. Stuart, R. Kimmig, et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J. Clin. Oncol., October 10, 2006; 24(29): 4699 - 4707. [Abstract] [Full Text] [PDF]

				M. Gore, A. du Bois, and I. Vergote Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental J. Clin. Oncol., October 1, 2006; 24(28): 4528 - 4530. [Full Text] [PDF]

				P. J. O'Dwyer and R. B. Catalano Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy J. Clin. Oncol., October 1, 2006; 24(28): 4534 - 4538. [Full Text] [PDF]

				J Pfisterer, A du Bois, J Sehouli, S Loibl, S Reinartz, A Reuss, U Canzler, A Belau, C Jackisch, R Kimmig, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann. Onc., October 1, 2006; 17(10): 1568 - 1577. [Abstract] [Full Text] [PDF]

				P. Sabbatini, J. Dupont, C. Aghajanian, F. Derosa, E. Poynor, S. Anderson, M. Hensley, P. Livingston, A. Iasonos, D. Spriggs, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res., September 15, 2006; 12(18): 5503 - 5510. [Abstract] [Full Text] [PDF]

				J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, U. Wagner, H. Bourgeois, W. Meier, S. Costa, J.-U. Blohmer, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst, August 2, 2006; 98(15): 1036 - 1045. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				D. S. Chi and R. R. Barakat Aggressive Surgery and Ovarian Cancer J. Clin. Oncol., May 20, 2006; 24(15): 2395 - 2396. [Full Text] [PDF]

				C. N. Krasner, M. Roche, N. S. Horowitz, J. G. Supko, S. I. Lee, and E. Oliva Case 11-2006 -- A 54-Year-Old Woman with a Mass in the Pelvis N. Engl. J. Med., April 13, 2006; 354(15): 1615 - 1625. [Full Text] [PDF]

				R. F. Ozols, M. A. Bookman, R. C. Young, G. de Castro Jr., I. M. Snitcovsky, M. H.H. Federico, D. K. Armstrong, B. Bundy, and J. Walker Intraperitoneal Chemotherapy for Ovarian Cancer N. Engl. J. Med., April 13, 2006; 354(15): 1641 - 1643. [Full Text] [PDF]

				R. P. Rocconi, J. M. Straughn Jr., C. A. Leath III, L. C. Kilgore, W. K. Huh, M. N. Barnes III, E. E. Partridge, and R. D. Alvarez Pegylated liposomal Doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist, April 1, 2006; 11(4): 336 - 341. [Abstract] [Full Text] [PDF]

				M. Markman, P.Y. Liu, M. L. Rothenberg, B. J. Monk, M. Brady, and D. S. Alberts Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer J. Clin. Oncol., March 20, 2006; 24(9): 1454 - 1458. [Abstract] [Full Text] [PDF]

				B. C.-Y. Zee Planned Equivalence or Noninferiority Trials Versus Unplanned Noninferiority Claims: Are They Equal? J. Clin. Oncol., March 1, 2006; 24(7): 1026 - 1028. [Full Text] [PDF]

				A. du Bois, B. Weber, J. Rochon, W. Meier, A. Goupil, S. Olbricht, J.-C. Barats, W. Kuhn, H. Orfeuvre, U. Wagner, et al. Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J. Clin. Oncol., March 1, 2006; 24(7): 1127 - 1135. [Abstract] [Full Text] [PDF]

				P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]

				M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775. [Abstract] [Full Text] [PDF]

				M. Markman and J. L. Walker Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment J. Clin. Oncol., February 20, 2006; 24(6): 988 - 994. [Full Text] [PDF]

				P. Sabbatini and D. R. Spriggs Consolidation for Ovarian Cancer in Remission J. Clin. Oncol., February 1, 2006; 24(4): 537 - 539. [Full Text] [PDF]

				E. R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and A. du Bois Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel J. Clin. Oncol., February 1, 2006; 24(4): 579 - 586. [Abstract] [Full Text] [PDF]

				M. Lockley, M. Fernandez, Y. Wang, N. F. Li, S. Conroy, N. Lemoine, and I. McNeish Activity of the Adenoviral E1A Deletion Mutant dl922-947 in Ovarian Cancer: Comparison with E1A Wild-type Viruses, Bioluminescence Monitoring, and Intraperitoneal Delivery in Icodextrin Cancer Res., January 15, 2006; 66(2): 989 - 998. [Abstract] [Full Text] [PDF]

				D. K. Armstrong, B. Bundy, L. Wenzel, H. Q. Huang, R. Baergen, S. Lele, L. J. Copeland, J. L. Walker, R. A. Burger, and the Gynecologic Oncology Group Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer N. Engl. J. Med., January 5, 2006; 354(1): 34 - 43. [Abstract] [Full Text] [PDF]

				G. Aravantinos, G. Fountzilas, P. Kosmidis, M. A. Dimopoulos, G. P. Stathopoulos, N. Pavlidis, D. Bafaloukos, C. Papadimitriou, S. Karpathios, V. Georgoulias, et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., July 1, 2005; 16(7): 1116 - 1122. [Abstract] [Full Text] [PDF]

				U. Matulonis, J. L. Abrahm, C.-M. Liu, and S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., March 24, 2005; 352(12): 1268 - 1269. [Full Text] [PDF]

				L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF]

				J. B. Engel, G. Keller, A. V. Schally, G. Halmos, B. Hammann, and A. Nagy Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215 Clin. Cancer Res., March 15, 2005; 11(6): 2408 - 2415. [Abstract] [Full Text] [PDF]

				P. G. Rose, S. Nerenstone, M. F. Brady, D. Clarke-Pearson, G. Olt, S. C. Rubin, D. H. Moore, J. M. Small, and the Gynecologic Oncology Group Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma N. Engl. J. Med., December 9, 2004; 351(24): 2489 - 2497. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]

				R. T. Penson, D. Sahani, and D. A. Bell Case 37-2004 - A 52-Year-Old Woman with Postmenopausal Bleeding and a Cystic Ovarian Mass N. Engl. J. Med., December 9, 2004; 351(24): 2531 - 2538. [Full Text] [PDF]

				P. A. Vasey, G. C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, D. Parkin, J. Paul, A. Hay, S. B. Kaye, et al. Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma J Natl Cancer Inst, November 17, 2004; 96(22): 1682 - 1691. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				A. K. Sood, R. Lush, J. P. Geisler, M. S. Shahin, L. Sanders, D. Sullivan, R. E. Buller, and J. I. Sorosky Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: Results of a Phase II Trial Clin. Cancer Res., September 15, 2004; 10(18): 6080 - 6085. [Abstract] [Full Text] [PDF]

				T. Onda, N. Katsumata, R. Tsunematsu, T. Yasugi, M. Mushika, K. Yamamoto, T. Fujii, T. Hirakawa, T. Kamura, T. Saito, et al. Cisplatin, Paclitaxel and Escalating Doses of Doxorubicin (TAP) in Advanced Ovarian Cancer: a Phase I Trial Jpn. J. Clin. Oncol., September 1, 2004; 34(9): 540 - 546. [Abstract] [Full Text] [PDF]

				J. S. Berek, P. T. Taylor, A. Gordon, M. J. Cunningham, N. Finkler, J. Orr Jr, S. Rivkin, B. C. Schultes, T. L. Whiteside, and C. F. Nicodemus Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer J. Clin. Oncol., September 1, 2004; 22(17): 3507 - 3516. [Abstract] [Full Text] [PDF]

				S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al. Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642. [Abstract] [Full Text] [PDF]

				G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926. [Full Text] [PDF]

				M. Gore Carboplatin Equals Cisplatin: But How Do I Prescribe It? J. Clin. Oncol., September 1, 2003; 21(17): 3183 - 3185. [Full Text] [PDF]